Dr. Reddy's Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5.61×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.80×	1.80×	1.92×	2.59×	2.41×
1.35×	1.35×	1.37×	1.92×	1.85×
4,611	5,360	4,796	5,116	5,028
14,302	13,432	11,984	15,217	12,122

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DRREDDY₹1,345.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.12L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	5.61
Current Ratio	2.41	2.59	1.92	1.80	1.80
Quick Ratio	1.85	1.92	1.37	1.35	1.35
Cash, Equiv & ST Investments	5,027.5	5,115.7	4,796.1	5,360.1	4,611.0
Working Capital	12,122.1	15,217.3	11,984.3	13,431.9	14,301.9

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.